Pure and Organic CBD & and Hemp Products

Effective medicine provided by mother nature

  • Powerful relaxant

  • Strong painkiller

  • Stress reduction
  • Energy booster

Why CBD?

More and more renowned scientists worldwide publish their researches on the favorable impact of CBD on the human body. Not only does this natural compound deal with physical symptoms, but also it helps with emotional disorders. Distinctly positive results with no side effects make CBD products nothing but a phenomenal success.

This organic product helps cope with:

  • Tight muscles
  • Joint pain
  • Stress and anxiety
  • Depression
  • Sleep disorder

Range of Products

We have created a range of products so you can pick the most convenient ones depending on your needs and likes.

CBD Capsules Morning/Day/Night:

CBD Capsules

These capsules increase the energy level as you fight stress and sleep disorder. Only 1-2 capsules every day with your supplements will help you address fatigue and anxiety and improve your overall state of health.

Order Now

CBD Tincture

CBD Tincture

No more muscle tension, joints inflammation and backache with this easy-to-use dropper. Combined with coconut oil, CBD Tincture purifies the body and relieves pain. And the bottle is of such a convenient size that you can always take it with you.

Order Now

Pure CBD Freeze

Pure CBD Freeze

Even the most excruciating pain can be dealt with the help of this effective natural CBD-freeze. Once applied on the skin, this product will localize the pain without ever getting into the bloodstream.

Order Now

Pure CBD Lotion

Pure CBD Lotion

This lotion offers you multiple advantages. First, it moisturizes the skin to make elastic. And second, it takes care of the inflammation and pain. Coconut oil and Shia butter is extremely beneficial for the health and beauty of your skin.

Order Now

Cannabis and Sleep

Studies and Research CBD



  • Studies and Research CBD
  • What the Science Says: CBD Clinical Trials
  • CBD studies with the greatest impact over the past year
  • In numerous studies, CBD was able to reduce the number of seizures, and We need more research but CBD may be prove to be an option for. All further studies of acute systemic CBD without prior stress showed anxiolytic effects or no effect [62, 65], the latter study involving intracerebroventricular rather . Introduction: Preclinical and clinical studies suggest that cannabidiol (CBD) found in Cannabis spp. has broad therapeutic value. CBD products.

    Studies and Research CBD

    This study reported a reduction in monthly drop seizures of Reported side effects were minor and similar to previously described studies. An ongoing open-label extension of this trial aims to understand the dose-response effect as well as the long-term efficacy of this therapy.

    This approval was specifically for the treatment of Lennox-Gastaut syndrome and Dravet syndrome, which are both severe forms of epilepsy that are often resistant to normal epilepsy medicine. The preclinical evidence strongly supports CBD as a potential treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder PTSD.

    This has been limited to acute administration rather than long-term use. Few human studies have yet investigated chronic CBD dosing and more research is needed in this area. A study using rats indicated that cannabidiol could disrupt the consolidation of specific and generalized fear memories. This study may help researchers understand the mechanism behind the effects in the endocannabinoid system, and may hold promise for sufferers of PTSD and other anxiety-related disorders. There is early evidence that cannabinoids have potential for treating autism or autism spectrum disorder ASD , a neurodevelopmental disorder that develops in infancy or childhood.

    The main symptom of ASD is impaired social interaction. Early signs can include unresponsiveness to people, avoiding eye contact or failure to respond to their own names. Researchers have found a potential link between autism and the cannabinoid 2 CB 2 receptors in the brain.

    Pennsylvania and Minnesota are the only states as of July to have approved medical cannabis treatments for autism. Research and evidence are still limited on this condition, with no large-scale clinical study results available and only single case study reports and animal research published to date. Schizophrenia is characterized by deficits in learning, memory, attention and executive functioning, and it can severely impact daily living.

    Antipsychotic drugs have limited benefits and thus novel treatments are being investigated. CBD has anti-inflammatory and antipsychotic-like properties, so may hold promise for schizophrenia.

    This indicates a need for further research prior to implementing treatments at this time. Cannabidiol is thought to modulate various neuronal circuits involved in drug addiction.

    Much of the work in this area has been done on pre-clinical or animal models, with limited human studies to evaluate. In animal studies, CBD was found to have an impact on the intoxication and relapse phase of opioid addiction. Data on its effect during the withdrawal phase remain conflicting and vary based on co-administration of other cannabinoids such as THC. A study of 24 smokers who wished to stop smoking and used an inhaler showed that 1 week and 2 weeks following treatment there was a reduction in cigarettes smoked as well as cravings.

    However, this was a short-term study with a limited population. Other single case studies have been documented on cannabis-related addictive behaviors but further research is needed to generalize the findings.

    The NIH recently authorized a 3. At what point is someone too high to get behind the wheel? The answer is complicated. Read the rest of the story here. Users say they take it for everything from muscle aches and anxiety to arthritis, epilepsy and Post Traumatic Stress Disorder. Read the article here. It seems like everywhere you turn cannabis or cannabis derivatives can be found. From ingredients in coffee and smoothies to being marketed as medicine, a cannabis craze seems to be sweeping the country.

    Click here to access the CMCR news archives. Cannabis was superior to placebo in reducing nausea and vomiting in patients refractory to other medications. Effect of dronabinol on central neuropathic pain after spinal cord injury: Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia.

    In bipolar disorder subjects, cannabis use was associated with better neurocognitive function, but the opposite was the case for the schizophrenia subjects. Depression is a Major Confounding Factor. The effects of nabilone on sleep in fibromyalgia: Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia.

    A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Smoked medicinal cannabis for neuropathic pain in HIV: Treatment of a hyperkinetic movement disorder during pregnancy with dronabinol. Effect of Delta 9 -tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans.

    Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: Participants rated cannabis as similar effective as other medications for the treatment of their symptoms. Systemic bioavailability of the cannabinoid CRA13 increased by more than 4-fold if taken together with a fat-rich meal.

    Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Synthetic deltatetrahydrocannabinol dronabinol can improve the symptoms of schizophrenia. Improvement in 4 of 6 participants, of whom 3 showed a significant improvement. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis.

    White matter integrity in adolescents with histories of marijuana use and binge drinking. Brain damage was less in alcohol users who used also cannabis than in alcohol only users. Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. A population-based case-control study of marijuana use and head and neck squamous cell carcinoma.

    Cannabinoid-induced effects on the nociceptive system: The study provides objective neurophysiological evidence that cannabinoids modulate the nociceptive system.

    Use of medical marijuana for treatment of severe intractable nausea after laparoscopic Roux-en-Y gastric bypass surgery: Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus.

    Improvement of appetite and reduction of nausea and vomiting by nabilone and dronabinol THC. Adjunctive nabilone in cancer pain and symptom management: Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol.

    Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation.

    Dramatic reduction in the severity of agitation and other behavioural symptoms. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy.

    Nabilone for the treatment of paraneoplastic night sweats: A prospective identification of neuropathic pain in specific chronic polyneuropathy syndromes and response to pharmacological therapy. Similar treatment effects and side effects of cannabinoids compared to other medications. Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain. A case report and review of the literature.

    Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. A medium dose of cannabis reduced pain, while a high dose increased pain induced by capsaicin. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial.

    Anorexia of aging in long term care: Dronabinol and marijuana in HIV-positive marijuana smokers: Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Dronabinol was as effective as ondansetron in reducing nausea and vomiting. Combination therapy was not more effective.

    Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial.

    Smoked cannabis was well tolerated and effectively relieved chronic neuropathic pain from HIV-associated sensory neuropathy. THC reduced intraoculat pressure and improved blood circulation in the retina. Significant reduction of pain and improvement of quality of life with nabilone. A Randomised Controlled Study. Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.

    The effect of extreme marijuana use on the long-term course of bipolar I illness: Cannabis decreased the number of depressed days and increased the number of hypomanic days. Long term marijuana users seeking medical cannabis in California The treatment of spasticity with Delta 9 -tetrahydrocannabinol in persons with spinal cord injury. Spasticity of patients who received cannabis and complied with the study protocol was significantly reduced compared to placebo.

    The synthetic cannabinoid nabilone improves pain and symptom management in cancer patients. Synergistic affective analgesic interaction between deltatetrahydrocannabinol and morphine. There was a synergistic effect between THC and morphine on the affective component of pain but not on the sensory component.

    Application of THC reduced the need of an opioid to treat postoperative pain but the difference to placebo was not significant. Dronabinol reduces signs and symptoms of idiopathic intracranial hypertension: Reduction in night-time agitation in actigraphy and in the neuropsychiatric inventory NPI.

    A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract Cannador for postoperative pain management. The optimal dose was 10 mg Cannador, effectively reducing postoperative pain without serious side effects. The effect of cannabis on urge incontinence in patients with multiple sclerosis: A pilot clinical study of Delta 9 -tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.

    THC was well tolerated in this pilot study of intrakranial cannabinoid administration. DeltaTHC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Five of the nine patients withdrew from the study due to side effects.

    Four patients experienced significant pain relief. Comparison of orally administered cannabis extract and deltatetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: An effective new possibility for treating chronic pruritus.

    Topical application of a cream with N-palmitoyl ethanolamine had a good antipruritic effect in most patients. Nabilone caused a significant reduction in pain and improvement of quality of life. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial.

    Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. Significant improvement in one case of intractable neuropathic pain and one case of refractory cinv.

    Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine Sativex in the treatment of pain caused by rheumatoid arthritis. Efficacy and safety of dexanabinol in severe traumatic brain injury: Survey of medicinal cannabis use among childbearing women: Postoperative nausea and vomiting was reduced by prophylactic administration of dronabinol and prochlorperazine. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: Cannabis use improves retention and virological outcomes in patients treated for hepatitis C.

    Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Evaluation of herbal cannabis characteristics by medical users: Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence: Moderate cannabis use had a positive effect of retention rates and abstinence from cocaine. Cannabinoids in multiple sclerosis CAMS study: Spasticity in the Ashworth scale was significantly reduced by an average of 1.

    Cannabis-based medicinal extract Sativex produced significant improvements in a subjective measure of spasticity which were maintained on long-term treatment with no evidence of tolerance. Beneficial effects of cannabis on spasticity in MS seem to be maintained over long-term treatment, with no evidence of tolerance. Smoked cannabis therapy for HIV-related painful peripheral neuropathy: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.

    Cannabis is effective in reducing pain and sleep disturbance in patients with multiple sclerosis related central neuropathic pain. Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. Deltatetrahydrocannabinol effects in schizophrenia: THC is associated with transient exacerbation in core psychotic and cognitive deficits in schizophrenia. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: Clinical improvement and reduction of immunosuppressive drug therapy in cannabis treated patients with crohn's disease.

    There were no significant effects of cannabinoids on the cytokine profiles examined. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Cannabis for dyskinesia in Parkinson disease: Survey on cannabis use in Parkinson's disease: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis?

    A double-blind, randomized, placebo-controlled study on patients. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.

    Urinary urgency, the number and volume of incontinence episodes, frequency and nocturia all decreased. Initial experiences with medicinal extracts of cannabis for chronic pain: Effect of Deltatetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. Cannabis improves night vision: A pilot study of dark adaptometry and scotopic sensitivity in kif smokers of the Rif Mountains of Northern Morocco.

    A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Impaired bladder control, muscle spasms and spasticity were improved by cannabis in some patients. A retrospective chart review. Short-term effects of cannabinoids in patients with HIV-1 infection: Randomised controlled trial of cannabis based medicinal extracts CBME in central neuropathic pain due to multiple sclerosis.

    Efficacy of two cannabis-based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: The effects of smoked cannabis in painful peripheral neuropathy and cancer pain refractory to opiods. Delta 9-tetrahydrocannabinol THC is effective in the treatment of tics in Tourette syndrome: Lack of analgesic efficacy of oral deltatetrahydrocannabinol in postoperative pain.

    Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis CAMS study: No effect of cannabinoids on spasticity as measured by the Ashworth scale, while patient-reported spasticity and pain decreased. THC reduced pain with low side effects; nabilone caused strong psychic side effects. The analgesic effect of oral deltatetrahydrocannabinol THC , morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions.

    Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. A topically applied cannabinoid receptor agonist HU reduced pain caused by capsaicin. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: Significant improvement of tics and obsessive-compulsive behavior after treatment with THC.

    Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Compared with placebo, neither THC nor plant-extract treatment reduced spasticity. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. A casuistic rationale for the treatment of spastic and myocloni in a childhood neurodegenerative disease: Cannabis was the most effective and readily available therapy to quit cocaine use.

    Combined treatment of Tourette syndrome with deltaTHC and dopamine receptor agonists. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: Antiemetic efficacy of smoked marijuana: Clinical investigation of deltatetrahydrocannabinol THC as an alternative therapy for overactive bladders in spinal cord injury SCI patients.

    Effects of smoked cannabis and oral deltatetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trials. A Three-Year Observational Study. An in-depth historical and scientific review of cannabis in migraine treatment. Results of an Anonymous Mail Survey. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. There was no effect on daily incontinence, but the cannabis extract was superior to placebo for nocturia.

    Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors. Cannabis use helped patients to quit crack use by reducing the craving symptoms.

    The use of cannabis as a mood stabilizer in bipolar disorder: A number of patients find cannabis marihuana useful in the treatment of their bipolar disorder. Activation of cannabinoid receptors can reduce L-DOPA-induced dyskinesia in man without aggravating parkinsonism.

    Smoking cannabis stopped hiccups that did not respond to usual medications on the 8th day. Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol dronabinol. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome.

    Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Marijuana to prevent nausea and vomiting in cancer patients: The effect of orally and rectally administered deltatetrahydrocannabinol on spasticity: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Treatment of spasticity in spinal cord injury with dronabinol, a tetrahydrocannabinol derivative.

    A phase II study of deltatetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Nabilone and metoclopramide were equally effective in reducing nausea and vomiting. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting.

    Marijuana as antiemetic medicine: Deltatetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Patients continued to loose, but the weight loss decreased in all groups; appetite and mood increased.

    Efficacy of tetrahydrocannabinol in patients refractory to standard anti-emetic therapy. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory.

    Increases in body weight during periods of active marijuana smoking were greater than predicted by caloric intake alone. A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. The patients notes a significant amelioration of symptoms when smoking cannabis.

    DeltaTHC in the treatment of spasticity associated with multiple sclerosis. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: A double-blind randomised cross-over comparison of nabilone and metoclopramide in the control of radiation-induced nausea. The administration of two or three active marijuana cigarettes during the social access period increased average daily caloric intake. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: Even for young children nabilone is an effective antiemetic, superior to domperidone.

    Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis.

    DeltaTHC proved clinically beneficial in two of five patients with intractable spasticity. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia.

    Antiemetic efficacy of levonantradol compared to deltatetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Levonantradol appears to be at least as effective an antiemetic as THC ; well-tolerated side-effects.

    What the Science Says: CBD Clinical Trials

    A logical start to this list is an overall update on CBD. of existing research, data, and studies with the intent to update. Research Studies By Indication/Ailment (Click Any Panel). Each panel below will forward you to a page with a list of published scientific studies. However, although research into the therapeutic effects of CBD is rapidly . Various studies done on CBD oils and other cannabis products.

    CBD studies with the greatest impact over the past year



    A logical start to this list is an overall update on CBD. of existing research, data, and studies with the intent to update.


    Research Studies By Indication/Ailment (Click Any Panel). Each panel below will forward you to a page with a list of published scientific studies.

    Add Comment